Pharmaceutical Technology

AUGUST 2, 2022

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. Following the demonstration at Samsung, the clinical trial of GreenLight’s Covid-19 booster vaccine is anticipated to commence this year.

Engineering 104

Engineering Manufacturing Pharmaceutical 104

Pharmaceutical Technology

DECEMBER 18, 2022

The 0.25mL dose of the booster vaccine could potentially be used in the European Union (EU) following authorisation in these children a minimum of three months following a previous Covid-19 vaccination. 1273.214, a bivalent Omicron-targeting Covid-19 vaccine of the company. 5), mRNA-1273. Free Whitepaper.

Medicine 121

Medicine Marketing Pharmaceutical Leads 121

Pharmaceutical Technology

AUGUST 15, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorisation for Moderna ’s Covid-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron), for use in adults aged 18 years and above. It comprises mRNA-1273 (Spikevax) and a vaccine candidate that acts on the SARS-CoV-2 virus’ BA.1

Side effects 85

Side effects Safety Government Pharmaceutical 85

European Pharmaceutical Review

AUGUST 22, 2023

The investment aims to improve vaccines and shorten the time it takes to produce medicines. Winners of a series of competitions centering on the aforementioned topics will obtain funding for UK medicines manufacturing. Seventeen new projects from the Innovate UK Transforming Medicine Manufacturing programme will benefit.

Medicine 86

Medicine Manufacturing Biopharma Competition 86

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Medicine 98

Medicine Food Leads Patients 98

Pharmaceutical Technology

AUGUST 28, 2022

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, is said to have infringed patents filed by Moderna between 2010 and 2016 for its mRNA technology. This technology was vital for developing Spikevax, an mRNA Covid-19 vaccine of Moderna. 5 Omicron-targeting bivalent booster vaccine for Covid-19, mRNA-1273.222.

Food and Drug Administration 98

Food and Drug Administration Food Marketing Pharmaceutical 98

Pharmaceutical Technology

JUNE 21, 2023

The Drug Controller General of India (DCGI) has granted emergency use authorisation (EUA) for Gennova Biopharmaceuticals’ Omicron-specific mRNA-based Covid-19 booster vaccine, GEMCOVAC-OM. The vaccine produced significantly higher immune responses when given as a booster. GEMCOVAC-OM was developed using indigenous platform technology.

Transportation 52

Transportation Government Pharmaceutical 52

pharmaphorum

AUGUST 25, 2022

Today on the pharmaphorum podcast, Editor in Chief Jonah Comstock welcomes Hedi Ben Brahim and Eric Quéméneur, CEO and chief science officer respectively of Transgene, to discuss cancer vaccines in general and Transgene’s recent work in the space in particular. . Podbean. .

52

52

Pharmaceutical Technology

JULY 6, 2022

The mRNA technology was used for the development of the Covid-19 vaccine. CureVac sought fair compensation for infringement of a portfolio of its intellectual property rights used to produce and sell BioNTech and Pfizer’s mRNA Covid-19 vaccine, Comirnaty. Topic sponsors are not involved in the creation of editorial content.

Distribution 72

Distribution Engineering Pharmaceutical Sales 72

Pharmaceutical Technology

FEBRUARY 23, 2023

GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. Topic sponsors are not involved in the creation of editorial content.

Manufacturing 115

Manufacturing Medicine Consulting Pharmaceutical 115

Pharma Leaders

JUNE 9, 2023

Biotech firm Promosome is the latest company to sue big pharma for infringing on its patent for messenger RNA (mRNA) technology during the rush to develop a COVID-19 vaccine, claiming in separate filings that Moderna and Pfizer reaped enormous profits using Promosome research. Promosome filed the suits Tuesday in the U.S.

Pharma 40

Pharma 40

Pharmaceutical Technology

OCTOBER 10, 2022

Health Canada has approved Pfizer ’s subsidiary Pfizer Canada and BioNTech’s bivalent Covid-19 vaccine, Comirnaty, as a 30?g 1-adapted bivalent vaccine. 5-adapted bivalent vaccine. 5-adapted bivalent vaccine. A clinical trial of the vaccine is currently underway in individuals aged 12 years and above.

Safety 59

Safety Pharmaceutical Manufacturing Leads 59

Pharmaceutical Technology

JANUARY 20, 2023

In 2020, Moderna made a net loss of $747 million while its investigational mRNA vaccines were under development. However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. billion in Covid-19 vaccine sales.

Manufacturing 98

Manufacturing Government Sales Pharmaceutical 98

Pharmaceutical Technology

APRIL 4, 2023

Gennova Biopharmaceuticals has applied for an emergency use authorisation (EUA) from the Drug Controller General of India (DCGI) for its mRNA-based Omicron-specific Covid-19 booster vaccine. Dubbed GEMCOVAC-OM, the needle-free vaccine will be delivered intradermally with the PharmaJet Tropis Precision Delivery System (PDS).

Safety 59

Safety Distribution Leads Pharmaceutical 59

Pharmaceutical Technology

DECEMBER 5, 2022

With the establishment of this Translational Science Hub, Queensland is set to become an international messenger ribonucleic acid (mRNA) vaccine hub. With an initial focus on enchaining mRNA technology and developing a vaccine for Chlamydia, the research at the hub is anticipated to commence in the first quarter of next year.

Government 98

Government Pharmaceutical Marketing Leads 98

Pharmaceutical Technology

SEPTEMBER 29, 2022

The mRNA-1273.222 vaccine comprises 25µg doses of mRNA-1273 (Spikevax) and a vaccine candidate against the BA.4/BA.5 Moderna has so far obtained authorisations for Omicron-targeting bivalent booster vaccine in the US, Canada, Europe, Australia, South Korea, Switzerland, Japan, Singapore, Taiwan and the UK.

Pharmaceutical 59

Pharmaceutical Medicine Marketing 59

Pharmaceutical Technology

OCTOBER 18, 2022

Moderna has entered an agreement with Gavi, the Vaccine Alliance, with regard to the delivery of Covid-19 vaccines to lower-income countries supported by the Gavi COVAX Advance Market Commitment (AMC). According to the deal, the parties will cancel pending orders under the existing Covid-19 vaccine supply agreement for this year.

Food and Drug Administration 52

Food and Drug Administration Food Pharmaceutical Leads 52

Pharmaceutical Technology

AUGUST 30, 2022

Moderna has obtaine d temporary authorisation from Swissmedic for its Omicron-targeting bivalent booster vaccine for Covid-19, Spikevax Bivalent Original/Omicron (mRNA-1273.214), for individuals aged 18 years and above. . The vaccine is indicated for active immunisation for the prevention of Covid-19.

Government 52

Government Safety Pharmaceutical Medicine 52

World of DTC Marketing

AUGUST 10, 2022

While trust in the pharma industry got a bump because of COVID vaccines, confidence about new drugs remains mixed. Monitor social media and identify possible topics for new content. DTC pharma marketers must acknowledge that people’s days of seeing a TV ad and running to their doctor to ask for the product are all but gone.

Marketing 252

Marketing Media Side effects Pharma 252

World of DTC Marketing

APRIL 14, 2022

“Were they vaccinated?”, In reviewing social media topics and comments on specific health conditions for clients, I determined that more than 75% of posts contained wrong or inaccurate information. One poset said that he had lost his mother and father to Covid, and immediately the trolls weighed in.

Media 218

Media Pharma Medical Marketing 218

Pharmaceutical Technology

OCTOBER 26, 2022

SK bioscience has signed a new collaboration agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop messenger ribonucleic acid (mRNA) vaccines for infectious diseases. The company has obtained the newest vaccine platform technologies such as bacterial culture, cell culture and genetic recombination.

Pharmaceutical 52

Pharmaceutical Manufacturing 52

Pharmaceutical Technology

JUNE 1, 2023

A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. Topic sponsors are not involved in the creation of editorial content.

Medicine 97

Medicine Side effects Manufacturing Leads 97

Pharmaceutical Technology

MARCH 23, 2023

China’s National Medical Products Administration (NMPA) has granted emergency use authorisation (EUA) for CSPC Pharmaceutical Group’s messenger RNA (mRNA) vaccine, SYS6006, to treat Covid-19. With this regulatory approval, CSPC Pharmaceutical is claimed to be the first company to receive approval for providing an mRNA vaccine in the country.

Pharmaceutical 52

Pharmaceutical Safety Leads Medical 52

Pharmaceutical Technology

AUGUST 23, 2022

5-adapted bivalent vaccine for Covid-19 in people aged 12 years and above. 1-adapted vaccine. The FDA also sought the vaccine’s pre-clinical and manufacturing data for addressing the SARS-CoV-2 virus’ evolution. 5-adapted bivalent vaccine will be made readily available for shipping. 5-adapted bivalent vaccine.

FDA 52

FDA Food and Drug Administration Distribution Manufacturing 52

Pharmaceutical Technology

AUGUST 17, 2022

These programmes will include therapies and vaccines in infectious disease and oncology areas. Preclinical data showed the potential of oRNA expression and delivery as a method for advanced development in various areas, including vaccines and oncology treatments. Topic sponsors are not involved in the creation of editorial content.

Pharmaceutical 59

Pharmaceutical Manufacturing Medicine Sales 59

Pharmaceutical Technology

NOVEMBER 30, 2022

in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m Topic sponsors are not involved in the creation of editorial content.

Government 59

Government Medical Pharmaceutical Leads 59

pharmaphorum

OCTOBER 6, 2022

The new version – dubbed Florence 2.0 – covers a broader range of topics. Along with advice on COVID-19 vaccines and treatments it can also share advice on mental health, give tips to de-stress, provide guidance on how to eat healthily and be more active, and quit tobacco and e-cigarettes, according to the WHO.

Healthcare 131

Healthcare Healthcare Leads Patients 131

Pharmaceutical Technology

NOVEMBER 21, 2022

This will aid in the production of new raw materials and possible clinical-grade assets to develop mRNA vaccines and therapies for infectious diseases, as well as other ailments with unmet needs. RVAC is currently developing mRNA-based vaccines against infectious diseases such as Covid-19.

Medicine 52

Medicine Manufacturing Pharmaceutical Leads 52

Pharmaceutical Technology

NOVEMBER 7, 2022

5 Omicron-targeting bivalent Covid-19 booster vaccine, mRNA-1273.222, for people aged 18 years and above. The 50µg vaccine is indicated for usage as a booster shot for active immunisation against Covid-19. Additionally, 28 days following inoculation, this vaccine showed enhanced neutralising antibody responses against Omicron BA.4/BA.5

Pharmaceutical 52

Pharmaceutical Medicine Management Marketing 52

Pharmaceutical Technology

AUGUST 24, 2022

5 Omicron-targeting bivalent booster vaccine for Covid-19. The submission is made for a 50µg booster dose of the vaccine for usage in adults aged 18 years and above. Irrespective of previous infection or age, the vaccine also showed neutralising antibody responses against the BA.4 1 subvariant.

FDA 52

FDA Food and Drug Administration Food Pharmaceutical 52

Pharma Marketing Network

DECEMBER 6, 2021

NEW YORK, December 6 th , 2021 (PRNEWSWIRE) – Tap Native, the leading health-focused content discovery platform, today unveiled a list of the top 20 most popular health topics viewed by consumer audiences in 2021. million unique URLs across the top 100 largest health websites in its network to determine which topics were viewed most.

Healthcare 52

Healthcare Healthcare Engineering Leads 52

Pharmacy Times

AUGUST 19, 2022

Ed Cohen, PharmD, FAPhA, drives a discussion around the new inclusion of infants as young as 6 months old within the COVID-19 vaccine recommendations and how to educate parents on the topic.

Education 37

Education 37

PharmaTech

AUGUST 31, 2022

Dearth of fill/finish capacity in the US, exacerbated by Covid and vaccine production, caused market dislocation but also opportunity. fast-growing, end-to-end CDMO service provider in Nashville, TN that offers development, testing and fill/finish cGMP manufacturing for sterile injectable and topical products.

Manufacturing 40

Manufacturing Marketing 40

Pharmaceutical Technology

MAY 12, 2023

BioNTech has ended its research collaboration with Matinas after its oral mRNA vaccine failed to demonstrate preclinical activity. Whilst BioNTech has shelved its oral mRNA vaccine project, shares were up this week following promising early results of a personalised mRNA vaccine for pancreatic cancer.

Leads 52

Leads Pharmaceutical Patients 52

PM360

MARCH 22, 2024

We’re featuring AI in this month’s issue as the topic can’t be ignored—generative AI is creating huge waves in the Pharma industry and it’s all we’re talking about. Vaccines are being made more quickly than ever with the help of algorithms and you may have even already asked an AI-powered chatbot about a medical condition or concern.

Ethics 52

Ethics Pharma Specialization Healthcare 52

Pharmaceutical Technology

MAY 24, 2023

Morphogenesis’s technologies include Immune Fx (IFx) personalised cancer vaccines and tumour microenvironment (TME) modulators. Morphogenesis’ lead personalised cancer vaccine, IFx-Hu2.0, Morphogenesis’ lead personalised cancer vaccine, IFx-Hu2.0, The company is also advancing its mRNA vaccine, IFx-Hu3.0,

Leads 52

Leads Patients Management Pharmaceutical 52

World of DTC Marketing

DECEMBER 28, 2020

First, let’s dispel a recent topic: telehealth. Once vaccination levels reach critical mass, people will once again return to their physician’s offices. Business magazines are writing about the “digital future” of healthcare but are consumers ready? Some are, but most aren’t.

Doctors 296

Doctors Side effects Marketing Electronics 296